<p>The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-?) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-? with preserved affinity to the hIFN-? receptor. The derivatives represent genetically modified variants of hIFN-?, where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-?, inactivated by physical or chemical methods.</p>
